Key result
Maternal application of topical diclofenac patches during the second and third trimesters of pregnancy was associated with antenatal closure of the ductus arteriosus and persistent pulmonary hypertension of the newborn.
Why the study?
NSAID use during the third trimester can cause premature constriction of the ductus arteriosus, but cases following maternal topical use require documentation.
Does maternal topical use of diclofenac during pregnancy cause premature constriction of the ductus arteriosus and persistent pulmonary hypertension of the newborn?
Case Report (n=1)
No
Does maternal topical use of diclofenac during pregnancy cause premature constriction of the ductus arteriosus and persistent pulmonary hypertension of the newborn?
Maternal use of topical diclofenac during the second and third trimesters of pregnancy can lead to severe fetal and neonatal complications, including premature closure of the ductus arteriosus and persistent pulmonary hypertension of the newborn.
Answers are grounded in this paper and cite their sources.
May warrant caution with topical diclofenac in later pregnancy; hypothesis-generating case report requiring confirmation.
Background: The use of non-steroidal anti-inflammatory drugs (NSAIDs) during the third trimester of pregnancy can cause premature constriction of the ductus arteriosus. This report describes a case of in utero narrowing of the ductus arteriosus (DA) diagnosed postnatally in a baby with Persistent Pulmonary Hypertension of the Newborn (PPHN), after maternal use of Diclofenac-Epolamine 140 mg patch during the second and third trimester. Case Presentation: A fetal ultrasounds revealed an enlarged hypertrophic right ventricle at 32 weeks of gestation. Detailed questioning of the mother highlighted that topical Diclofenac (FLECTOR®) had been used at 26 and at 31 weeks of gestation. An echocardiography performed 8 h postnatally showed supra-systemic pulmonary hypertension, a restrictive ductus arteriosus and a dilated right ventricle. The newborn was treated by inhaled nitric oxide and oral Sildenafil and was discharged from hospital on day 24. He had a complete normalization of his pulmonary vascular resistance on day 48. Conclusion: This case illustrates the potential fetal and neonatal complications associated with maternal topical Diclofenac medication during pregnancy resulting in antenatal closure of the DA.
No takes yet. Share an insight, caveat, or question.
Duc et al. (2021) conducted a case report in Persistent Pulmonary Hypertension of the Newborn (PPHN) (n=1). Topical Diclofenac (Diclofenac-Epolamine 140 mg patch) was evaluated on Development of PPHN and narrowing of the ductus arteriosus. Maternal application of topical diclofenac patches during the second and third trimesters of pregnancy was associated with antenatal closure of the ductus arteriosus and persistent pulmonary hypertension of the newborn.
Synapse has enriched 10 related papers. Consider them for comparative context: